8-K - Immuneering Corporation | StockGist

Current Report Details

Event Type

Material Agreement+3 More

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

. Entry Into a Material Definitive Agreement. On September 24, 2025, Immuneering Corporation (the “Company”) entered into a securities purchase agreement (the “

Material Agreement

$25.0M$75.0M

Source Document

3.02

. Unregistered Sales of Equity Securities. The information contained in Item 1.01 of this Current Report is incorporated by reference into this Item 3.02. On Se

Securities Issuance

8.01

. Other Events. On September 24, 2025, the Company announced updated interim data from its ongoing Phase 2a clinical trial arm evaluating atebimetinib (formerly

Other Event

Company, pursuant to which the Company

9.01

. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Securities Purchase Agreement, dated as of September 24, 2025, by and between Imm

Exhibits Only

Source Document

Exhibits (3)

10.1

EXHIBIT 10.1

8-K

FORM 8-K

99.1

EXHIBIT 99.1